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Superﬁcial digital ﬂexor tendon lesion is an important cause of lameness in equine
athletes. Although numerous treatments have been described, few are effective at
promoting signiﬁcant improvement in the quality of the extracellular matrix. Therefore,
great potential remains for recurrence and in certain cases, an abrupt end to the horse’s
athletic career. Recently, several experiments have focused on the therapeutic potential
of mesenchymal stem cells (MSCs) in cases of tendon lesions. This study aimed to
evaluate the effect of adipose tissue-derived MSCs in the treatment of induced tendinitis
of the superﬁcial digital ﬂexor tendon in horses by clinical, ultrasonographic, histo-
pathological, and immunochemical analyses. Tendinitis was induced in both thoracic
limbs of eight mares by administration of collagenase solution and adipose tissue was
collected from the tail base for MSCs isolation and expansion, which were used during
cellular therapy on only one limb 30 days after lesion induction. No differences occurred
between the groups regarding the clinical and ultrasonographic analyses; however,
histopathological evaluation revealed a signiﬁcant improvement in tendon ﬁber orga-
nization and diminished inﬂammatory inﬁltrate, whereas immunohistochemical analysis
showed increased expression of type I collagen in the treated group as compared with
controls. The cellular therapy model implanted in this experiment promoted increased
perivascular inﬂammatory inﬁltrate, ﬁbroblastic density, neovascularization, and quali-
tative healing improvement of tendon extracellular matrix, in terms of ﬁber orientation
and type I/III collagen ratio; moreover, it was considered to be a safe and viable process.
 2011 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction because of its high incidence, prolonged recovery period,Tendinitis of the superﬁcial digital ﬂexor tendon (SDFT)
is an extremely important afﬂiction for equine athletes in
all types of sports [1]. Tendinitis is an important cause of
lameness and diminished performance in equine athletesos Carvalho, MSc,
y, School of Veteri-
niversity (UNESP),
attos Carvalho).
sevier OA license. and high rate of recurrence [2]. Possible explanations for
the slow healing of tendons and, in the majority of cases,
the resulting formation of mechanically inferior extracel-
lular matrix are probably because of the fact that tendon is
a minimally vascularized tissue, presents cells that exhibit
diminished mitotic activity, and the presence of few
progenitor cells in the tissue [3,4].
Recurrences are related to the nonregeneration of
tendon tissue and the production of a matrix of collagen
ﬁbrils that are smaller in diameter and of inferior quality,
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promote healthy tendon tissue regeneration should
produce a reduction in recurrence rates as compared with
those that promote the formation of scar tissue [5].
Knowledge concerning tendon repair and its implica-
tions for the athletic capacity of the individual horses
affected by tendinitis has stimulated research regarding
new therapies applied to this tissue. Cellular therapy using
mesenchymal stem cells (MSCs) has shown promising
results in several published works [1,2,6,7]. In cases of
tendon lesion in horses, themajority of published data have
focusedmainly on the therapeutic potential ofMSCsderived
from bone marrow and adipose tissue, even though studies
indicate the possibility of other sources of MSCs in adult
tissue, including brain tissue, dermis, periosteal, skeletal
muscle, synovial, trabecular bone, and vascular tissue [8].
The most abundant and accessible source of stem cells is
adipose tissue [9], justifying the expressive interest in the
development of cellular therapy involving this source.
The stromal vascular fraction is a heterogenous cell
population derived from adipose tissue that includes
endothelial and epithelial cells, preadipocytes, and certain
progenitor cells. These progenitors, adipose-derived MSCs,
have shown multiple differentiation potential similar to
bone marrow-derived MSCs [10].
MSCs implantation causes an increase in the number of
progenitor cells than normally present in tendon tissue,
thereby improving the potential for regeneration [11]. The
immunomodulatory properties of MSCs translate into anti-
inﬂammatory effects in vivo and numerous animal studies
have demonstrated that exogenously administered MSCs
attenuate inﬂammation and facilitate regeneration of
injured tissue [12].
Till recently, existing reports have only described the
clinical use of adipose tissue-derived MSCs isolated from
horses and expanded in the laboratory, as outlined by
Leppänen et al. [13]; however, no controlled study of
equine tendon therapy using these cells exists. To investi-
gate this, collagenase was used to induce tendinitis in the
SDFT, followed by adipose tissue collection for the isolation
of mononuclear cells and posterior culture of progenitor
cells. After intralesional implantation ofMSCs in the treated
group, clinical, ultrasonographic, histological, and immu-
nohistochemical analyses were conducted to compare the
treatment and control groups. It is our hypothesis that the
injection of progenitor cells improves tendon healing by
increasing the number of stem cells at the lesion site,
thereby favoring the synthesis of extracellular matrix
similar to healthy tendon tissue, the reduction in tendon
inﬂammation, and increased concentrations of type I
collagen, leading to improved quality in tendon repair.
2. Materials and Methods
2.1. Animals
Eight clinically normal young mares of undeﬁned breed
(age: 2-3.5 years) were used in the study. The mares were
examined clinically and by ultrasonography to ensure that
they presented no preexisting tendon damage. The exper-
imental protocol was approved by the Committee of Ethics
and Animal Welfare of the School of Veterinary Medicineand Animal Science, São Paulo State University, Brazil, and
was performed under international guidelines for the care
and use of experimental animals. All the mares were
submitted to the same procedures, with differences only in
the time of biopsy. To further improve the elucidation of the
experiment, the horses were divided into two groups of
four mares each: Group A (GA), in which the mares were
submitted to ultrasound examinations at 0, 2, 4, 6, and 8
weeks and a bilateral biopsy of the digital ﬂexor tendon
performed 60 days after lesion induction; and Group B
(GB), in which the mares were submitted to ultrasound
examinations at 0, 2, 4, 6, 8, 10, to a maximum of 21 weeks
and a bilateral biopsy of the digital ﬂexor tendon after
lesion induction for posterior histopathological and
immunohistochemical analyses. The tendon biopsies were
obtained on days 60 and 150 after collagenase application
to investigate tendon healing evolution.
2.2. Tendinitis Induction
All the mares were subjected to lesion induction in the
SDFTof both thoracic limbs in the region of themiddle one-
third of the metacarpal region. Lesion induction was ach-
ieved by local administration of 2.5 mg or 690 IU of type I
collagenase (Collagenase type 1: C-0130, Sigma Pharma-
ceutical, St. Louis, MO, USA) diluted in 1.0 mL of sterile
water, guided by ultrasound equipment (Logiq 3, General
Electric, Sangdaewon-Dong, Korea), similar to the method
described by Maia et al. [14]. Prior sedation of the mares
was achieved with 10% xylazine (Sedazine, Fort Dodge,
Campinas, São Paulo, Brazil) at a dosage of 0.8 mg/kg, the
region around the collection site was shaved and asepti-
cally prepared, and local anesthesia was performed by
perineural blockage of the lateral andmedial palmar nerves
in the proximal metacarpal region, using 2 mL of 2% lido-
caine chlorhydrate (Xylestesin, Cristália Produtos Químicos
e Farmacêuticos Ltda, Itapira, São Paulo, Brazil) without the
application of a vasoconstrictor at each point.
2.3. Adipose Tissue Collection
The region above the dorsal gluteal muscle, at the base
of the tail, was chosen as the adipose tissue collection site
because of the availability of material, the absence of large
veins, and easy access. The mares were sedated with
xylazine (1 mg/kg, i.v.), followed by inﬁltration of the skin
and subcutaneous tissues with an anesthetic, 2% lidocaine
chloride, using an inverted L-block. An incision of approx-
imately 10 cm in length was made parallel to and approx-
imately 15 cm below the spinal column, permitting
visualization of a layer of adipose tissue between the skin
and musculature. Approximately 5 mL of adipose tissue
was collected and stored in a sterile 50-mL conic ﬂask
containing Roswell Park Memorial Institute - 1640 medium
(Sigma Chemical Co., St. Louis, MO, USA), such that the
sample was entirely immersed. The skin was sutured with
nylon suture in simple isolated stitches.
2.4. Isolation of Stromal Vascular Fraction Cells
The sample materials were then subjected to successive
washes with phosphate buffered saline (PBS) in sterile
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To isolate the cells, the extracellular matrix was then sub-
jected tomechanical separation using a No.15 scalpel blade
(Wuxi Xinda Medical Device Co., China) and the digestive
action of 0.02% of type I collagenase (Gibco, Grand Island,
NY, USA) in RPMI-1640 medium, in a humidiﬁed incubator
at 37C, under 5% CO2 for 12 hours, followed by neutrali-
zation of the enzyme with Knockout Dulbecco’s modiﬁed
Eagle’s medium (Gibco, Grand Island, NY, USA) containing
10% fetal bovine serum (Gibco, Grand Island, NY, USA). This
solution was centrifuged with a relative centrifugal force of
260 g for 10minutes and the supernatant was aspirated and
added to Dulbecco’s phosphate buffered saline (Gibco,
Grand Island, NY, USA) and homogenized for future
centrifugation. After this procedure, the number of cells
was quantiﬁed in an improved Neubauer counting chamber
(Labor Optik, Germany) to evaluate cellular viability by the
standard exclusion test using 0.02% trypan blue (Trypan
Blue Stain, Gibco, Grand Island, NY, USA).
2.5. MSC Culture
Cells of the stromal vascular fraction were cultured at
a density of 105 cells/cm2 in 25-cm2 culture plates and these
weremaintained in an incubator at 37C under 5% CO2 with
Knockout Dulbecco’s modiﬁed Eagle’s medium and 10%
fetal bovine serum culture medium. The medium was
changed every 3 days and when a minimum conﬂuence of
70% of the plate occurred, trypsinizationwas conducted, on
the basis of a technique previously described in horses [15].
The cells (100 mL) were collected and transferred to
a hemolysis tube for cell counts, where the number of cells
was quantiﬁed using a hemocytometer and cellular viability
was evaluated by the trypan blue exclusion test. The
remainder was transferred to three 25-cm2 culture plates
that were further incubated at 37C under 5% CO2. Cell
cultivation was maintained until the fourth passage using
samples fromonehorse anduntil the secondpassage for the
remaining horses, after which cell counts and immuno-
phenotypic characterization of MSCs were conducted.
2.6. Flow Cytometry Analysis
Flow cytometry was performed in all the passages
tested (ﬁrst to fourth) in FACSCalibur (BD, Franklin Lakes,
NJ, USA) equipment using the mouse anti-rat CD90-
ﬂuorescein isothiocyanate (FITC) (Caltag Laboratories,
Burlingame, CA, USA) monoclonal antibody, as well as tests
with speciﬁc monoclonal mouse anti-horse CD13 (AbD
Serotec,Kidlington, Oxford, UK) andmouse anti-horseCD44
(AbD Serotec, Kidlington, Oxford, UK) antibodies, which
were marked with goat anti-mouse immunoglobulin
G (IgG)-FITC IgG (Molecular Probes, Eugene, OR, USA)
secondary monoclonal antibodie. Randomized analysis of
variance (ANOVA) was performed to verify statistically
signiﬁcant differences (P < .05) regarding the markers used
by comparing their expression in the different passages.
2.7. MSC Implantation
Cell implantation was performed by randomized selec-
tion of the right or left limb of each mare and thisinformation remained blinded. Thirty days after tendinitis
induction, implantation of approximately 10  106 adipose
tissue-derivedMSCs was performed at the lesion site of the
chosen leg, a procedure similar to that described by Maia
et al., to achieve lesion induction [14]. Before cell implan-
tation, puncture of the jugular vein was performed to
collect blood in a tube not containing any anticoagulant (BD
Vacutainer Serum, Franklin Lakes, NJ, USA), and after 30
minute at rest, coagulation started, with the precipitation
of red blood cells and supernatant containing autologous
serum, 0.5 mL of which was removed to dilute the MSCs.
These were quickly placed in refrigerated thermal
containers and immediately carried to the location of
cellular implantation. Guided by ultrasound equipment,
the 21-G needle was positioned at the center of the lesion
site and coupled to the syringe containing the cells was
injected into one of the thoracic limbs of each mare. No
substance was administered to the contralateral limb,
which was denominated as the control limb.
Themares were followed up daily for aweek after lesion
induction, then weekly until the time of the biopsy. The
presence of sensitivity was evaluated and scored as follows:
0: absent; 1: slight; 2: moderate; and 3: severe.
2.8. Physical Activity
After cellular implantation, the mares were submitted
to progression-controlled physical activity, on the basis of
the following scheme:
 Day 0 to 44: stall rest (GA and GB).
 Day 45 to 60: walking for 15 minutes, once a day (GA
and GB).
 Day 61 to 90: walking for 15 minutes, twice a day (GB).
 Day 91 to 120: walking for 30 minutes, once a day (GB).
 Day121 to 150:walking for30minutes, twice a day (GB).2.9. Ultrasonographic Control
Ultrasonographic evaluations were performed with
a 7.5-MHz linear transductor, to evaluate lesion induction
and tissue repair. Ultrasound analysis was carried out
before collagenase administration, before and after cellular
implantation at 0, 2, 4, 6, and 8weeks in GA or at 0, 2, 4, 6, 8,
10, to a maximum of 21 weeks after lesion induction in GB,
until the end of the experimental period (60 days, GA), and
150 days after injury induction (GB). The following
parameters were measured: tendon area; lesion area;
percentage of lesioned area in the interior of the tendon;
echogenic pattern, graduated from 0 to 4, according to
Genovese et al. [16]; and tendon ﬁber alignment. The
images obtained were recorded for posterior comparison
between the different time intervals and groups of mares.
2.10. Statistical Analysis
Statistical analysis was performed by two-way repeated
measures ANOVA (P < .05) with random effects, incorpo-
rating the dependency between observations at the
different time points and between observations for the
same mare, with respect to the continuous quantitative
Table 1
Score used for each variable during the histopathological evaluation of the
healing process of the SDTF in the MSCs-treated and control limbs
Variables Scores and Criteria
Fibroblastic density 0: Sparse (normal)
1: Slight increase
2: Moderate increase
3: Sheets of ﬁbroblasts
Neovascularization (vessel numbers) 0: Normal
1: Slight increase
2: Moderate increase
3: Severe increase
Inﬂammatory inﬁltrate 0: None
1: Slight increase
2: Moderate increase
3: Severe increase
Tissue organization 0: None
1: Discretely organized
2: Moderately organized
3: Organized (normal)
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lesion area.
2.11. Biopsy
The biopsy was performed in core lesions of the tendon,
from the lateral direction at two different times, according
to the group of mares. In GA, the biopsy was performed on
day 60 after lesion induction, whereas in GB, collection of
tendon material was performed on day 150 after lesion
induction. Themares were submitted to general anesthesia,
including preanesthetic medication with 10% xylazine
(1.1 mg/kg, i.v.), induction with guaiacol glyceryl ether
(Vetec Química Fina Ltda, Duque de Caxias, Rio de Janeiro,
Brazil) at a dosage of 100 mg/kg, i.v., followed by ketamine
(Dopalen, Vetbrands, Paulínia, São Paulo, Brazil) at a dosage
of 2.2 mg/kg, i.v., andmaintenance by inhalatory anesthesia
using isoﬂurane (Isoﬂuorano, Cristália Produtos Químicos e
Farmacêuticos Ltda, Itapira, São Paulo, Brazil). Local anes-
thetic blockage of the median, medial antebrachial cuta-
neous, and ulnar nerves was performed by 20 mL of 2%
lidocaine without the application of a vasoconstrictor. The
biopsy was performed with the horse positioned in right
lateral recumbency and an incision of approximately 5 cm
in length was made in both the skin and subcutaneous
tissue for later identiﬁcation and individualization of the
tendon with the aid of hemostatic tweezers. After locali-
zation of the injured area, 1 cm3 of core lesionwas biopsied
by resection and was immediately placed in a ﬂask con-
taining 10% buffered formalin (Embramac, Empresa Brasi-
leira de Materiais Cirúrgicos, Itajaí, Santa Catarina, Brazil).
Previous marking of the height of the lesion in the limb and
ultrasound images were used to identify the exact site for
performing the biopsy. In general, tissue was collected
between the central and peripheral portion of the tendon,
involving the entire area of the lesion, a transverse section
of 40% of the total tendon area. Suturing of the paratenon
was performed in a single continuous stitch using Vicryl 2-
0 (Eletro-Light Ltda, Manaus, Amazonas, Brazil) suture and
suturing of the skin in simple interrupted stitches using
nylon suture. After the surgical procedure, a compressive
bandage was applied to the metacarpal region for 48 hours
and the mares were maintained in the stall for 4 weeks.
During the postoperative period, daily wound dressing was
performed until the removal of sutures on day 14. Phen-
ylbutazone (Equipalazone, Vitalfarma Ltda, São Sebastião
do Paraíso, Minas Gerais, Brazil), a nonsteroidal anti-
inﬂammatory medication, was administered at a dosage
of 4.4 mg/kg i.v., every 24 hours for 5 days.
2.12. Histopathological Analyses
Processing of the tendon fragments was performed
following conventional methods for parafﬁn inclusion and
histopathological sectioning, which was then followed by
hematoxylin and eosin or Masson’s trichrome staining.
Histopathological analysis was performed by using an
optical microscope, with the pathologist blinded to the
group. For each speciﬁc type of analysis, two slides of
biopsied tendon tissue were prepared. The density and
characteristics of the ﬁbroblasts, the presence and type of
inﬂammatory inﬁltrate, neovascularization, and tissueorganization were analyzed using the criteria described by
Maia et al. [14]. Data relative to the histological variables
(Table 1), classiﬁed by scores (0-3), were analyzed and
compared between groups using the Wilcoxon nonpara-
metric test, followed by the KolmogoroveSmirnov test. The
results obtained are presented as the median value of the
scores obtained in each SDFT belonging to both MSCs-
treated and control limbs per group (GA and GB). All tests
were performed using the GraphPad InStat 3.05 statistical
software package (Graph Pad Software Inc., San Diego, CA,
USA) with P < .05.
2.13. Immunohistochemical Analyses
To perform immunohistochemical analysis, fresh 3-mm
sections were obtained from parafﬁn blocks and placed on
ImmunoSlides (EasyPath, São Paulo, Brazil) histological
slides. For each speciﬁc type of analysis, two slides of
biopsied tendon tissue were prepared. The process was
initiated with deparafﬁnization in successive xylol washes,
three immersions in absolute alcohol, followed by
decreasing concentrations (95% and 85%) of alcohol solu-
tion, after which antigen retrieval was performed by
enzymatic digestion with 1% pepsin (pH: 1.8) in a heater at
60C for 10 minutes, followed by 50 minutes at 37C.
Endogenous peroxidase blockage was achieved with
hydrogen peroxide (3%) in methanol for 20 minutes, fol-
lowed by 10 washes with distilled water and twowashes of
5 minutes in tris(hydroxymethyl)aminomethane (pH: 7.4).
After blocking peroxidase, followed by a blockade of
speciﬁc binding with 3% milk powder for 1 hour in a heater
at 27C, the slides were subsequently washed with TRIS.
Incubation of primary antibodies was performed for 18
hours (overnight) at 4C, using polyclonal anti-bovine
collagen for collagen types I (puriﬁed rabbit anti-bovine
type I collagen, Novotec, Saint Martin La Garenne, France)
and III (puriﬁed rabbit anti-bovine type III collagen, Novo-
tec, Saint Martin La Garenne, France). The dilutions used
were 1:2000 and 1:1000, respectively. The secondary
antibody EnVision (Dako, Carpinteria, CA, USA) was incu-
bated at room temperature for 1 hour. The material was
then incubated with the chromogen DAB (Dako,
Fig. 1. Histopathological sections at 60 days. (A) Control limb (GA): moderate mononuclear perivascular inﬁltrate and greater cellularity (greater number of
nuclei) in the tendon. Unaligned extracellular matrix (hematoxylin and eosin [HE], 20 magniﬁcation). (B) Control limb (GA): presence of noncollagenized
conjunctive tissue, presence of perivascular inﬂammatory inﬁltrate, and greater cellularity (Masson’s trichrome, 20 magniﬁcation). (C) Treated limb (GA):
parallel arrangement of collagen ﬁbers similar to healthy tendon, lower cellularity as compared with control group (HE, 20 magniﬁcation). (D) Treated limb
(GA): greater collagen deposits (red staining) in the tendon (Masson’s trichrome, 20 magniﬁcation).
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Counterstaining was performed with hematoxylin. To
determine collagen expression in the samples collected
from the tendons of the control and treatment groups, ﬁve
ﬁelds of each fragment were evaluated. These were
obtained by optical microscopy of the slides containing
tendon tissue at 400 magniﬁcation. The ﬁve ﬁelds were
selected at opposing extremities of the slide, with the ﬁfth
ﬁeld at the center.
In each ﬁeld, the percentage of labeled cells was
measured using Leica Qwin 3.0 (Leica Microsystems,
Wetzlar, Germany) software through a binary image
processor, during thedetectionof collagen types I and III in the
stained regions. The results are presented as a percentage of
stainedregionsperﬁeld. Fiveﬁeldswereanalyzedonthebasis
of optical microscopy of tendon tissue slides at 400magni-
tude. Theseﬁveﬁeldswere selected from the four extremities
of the slide, with the ﬁfth ﬁeld of vision at the center.
Regarding the statistical analysis of immunohistochemical
characteristics (collagen type I and type III), two ANOVAs
were performed, one for the biopsy data of GA and the other
for GB. The design was randomized blocks, comparing the
treated and control groups, with 20 repetitions.
3. Results
Adipose tissue was successfully collected from all
the horses and a mean of 2 g of material was collected
from each tissue. The skin incisions healed withoutcomplications in all mares, except one, inwhom dehiscence
of the cutaneous suture occurred during the postoperative
period. In this mare, the wound was cicatrized by second
intention.
The number of MSCs that were viable during cell culture
varied between 9.1  106 and 17.8  106 cells (mean of
14.35  106 cells) in the ﬁrst passage and 10.2  106 and
52.9  106 cells (mean of 36.53  106 cells) in the second
passage. After cell counts and calculation of the cellular
viability of the second passage, 10  106 adipose tissue-
derived MSCs were separated and diluted in 0.5 mL of
autologous serumandquicklyplaced in refrigerated thermal
containers containing ice for immediate use in each mare.
Flow cytometry analysis revealed CD90 expression in all
the passages tested (ﬁrstefourth), determining interspe-
cies cross-reactivity between rats and horses. CD44 also
expressed a reaction with MSCs in all the passages;
however, greater expression showing a statistically signif-
icant difference was observed as the number of passages
increased. Regarding the analysis of surface marker CD13,
no reaction was obtained with MSCs derived from equine
adipose tissue [15].
Tendon implantation of theMSCswas performed and no
side effects resulting from the injection occurred. Each
mare received a single dose of MSCs at the lesion site
guided by ultrasound equipment.
Tendinitis induced by collagenase implantation was
initially diffuse, becoming more organized over time.
During cellular implantation, the lesion was much more
Fig. 2. Histopathological sections at 150 days. (A) Control limb (GB): lower cellularity in the tendon as compared with the control group at 60 days. Greater
parallel arrangement of collagen ﬁbers and less intense perivascular inﬂammatory inﬁltrate (HE stain, 20magniﬁcation). (B) Control limb (GB): greater deposits
of extracellular matrix (red staining) were observed as compared with the control group at 60 days, although less intense than in the treated group at 150 days
(Masson’s trichrome, 20magniﬁcation). (C) Treated limb (GB): aspect similar to normal tendon, with the presence of parallel arranged extracellular matrix and
minimal cellularity (HE, 20 magniﬁcation). (D) Treated limb (GB): greater collagen deposits (red staining) in the tendon as compared with the control group
(Masson’s trichrome, 20 magniﬁcation).
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ations in echogenicity were evident in the ultrasound
examinations of treated thoracic limbs, which can be
explained by the high cell concentration of the solution
administered. In the control limb, the ultrasound image of
tendinitis remained organized and anechoic. No visible
clinical differences occurred regarding sensitivity, lame-
ness, or in the circumference of the middle one-third of the
metacarpal region between the treatment and control
groups.
No difference was detected between the treated and
control limbs in both groups (GA and GB) and the sono-
graphic evaluation of the tendon area, lesion area,
percentage of damaged area, degree of injury, and the
degree of tendon ﬁber parallelism, that is, the cell therapy
used in this experiment demonstrated an improvement
during analysis of ultrasound imaging. The period of 150
days after lesion induction was not sufﬁcient for the
lesioned area to reveal a normal echopattern in both treated
and control limbs. Moreover, analysis of the ultrasono-
graphic images revealed no improvement in the parallelism
of the tendon ﬁbers from the treatment and control groups.
In the histopathological analysis of GA, the MSCs-
treated group had a slight to moderate increase in peri-
vascular inﬂammatory inﬁltrate (median, 1.5), a slight to
moderate increase in ﬁbroblastic density for ﬁbroblast
sheets (median, 1.5), a slight to moderate increase in tissue
organization (median, 1.5), and a moderate to strongincrease in neovascularization (median, 2.5). During anal-
yses, important morphological aspects were observed in
GA under MSCs treatment: more well-deﬁned collagen
ﬁbers in the treated limbs, together with greater organi-
zation and alignment, more representative crimps, and
more elongated nuclei in the ﬁbroblasts as compared with
the control group. The blood vessels tended to elongate
longitudinally, in the direction of the force exerted on the
tendon (Fig. 1).
On the basis of the histopathological ﬁndings obtained
for the GA controls, therewas amoderate to severe increase
in perivascular inﬂammatory inﬁltrate (median, 2.5),
a moderate to strong increase in ﬁbroblastic density for
ﬁbroblast sheets (median, 2.5), discretely organized tissue
(median, 0.5), and a slight to moderate increase in neo-
vascularization (median, 1.5). Differences (P < .05) between
treated and control tendons in GA were observed in all
analyses (inﬂammatory inﬁltrate, ﬁbroblastic density,
tissue organization, and neovascularization).
Regarding the histopathological ﬁndings for GB, the
MSCs-treated group showed a slight increase in peri-
vascular inﬂammatory inﬁltrate (median, 0.5), a slight
increase in ﬁbroblastic density for ﬁbroblastic sheets
(median,1.0), normal tissue organization (median, 3.0), and
a slight increase in neovascularization (median, 1.0).
The histopathological ﬁndings for GB controls showed
a slight to moderate increase in perivascular inﬂammatory
inﬁltrate (median, 1.5), a moderate increase in ﬁbroblastic
Fig. 3. Immunohistochemistry after 150 days of the experiment. (A) Immunohistochemistry for type I collagen, treated limb (400 magniﬁcation). (B) Immu-
nohistochemistry for type I collagen, control limb (400 magniﬁcation). (C) Immunohistochemistry for type III collagen, treated limb (400 magniﬁcation). (D)
Immunohistochemistry for type III collagen, control limb (400 magniﬁcation).
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nization (median, 2.0), and a slight increase in neo-
vascularization (median, 1.0). Differences (P < .05) between
the treated and control tendons in GB were observed in
inﬂammatory inﬁltrate, ﬁbroblastic density, and tissue
organization analysis. No difference between the treated
and control tendons in GB was only observed in the
neovascularization analysis.
In both GA and GB, the limbs submitted to cellular
therapy presented better histopathological evaluations for
the tendons in relation to the control limbs; however, the
treated limbs of mares in GB presented an aspect much
more representative of normal tendon than the treated
limbs of mares in GA. The former showed the presence of
parallel arrangements of the extracellular matrix and
minimal cellularity, indicating that tendon therapy
involving adipose-derived MSCs resulted in improved
organization of the extracellular matrix (Fig. 2).
Measurement of the percentage of the stained areas per
ﬁeld using type I and III collagen markers was achieved by
Leica Qwin 3.0 imaging software (Leica Microsystems).
Analysis of the images demonstrated a signiﬁcant differ-
ence (P < .05) for the type I collagen marker for both
periods that the biopsies were performed, with greater
expression in treated tendons (mean value, 7.39) and lower
expression in controls (mean value, 5.14) of GA. Analysis
of the images also demonstrated signiﬁcance differences
(P < .05) for type I collagen expression in treated tendons
(mean value, 7.26) of GB than in controls (mean value, 4.11).
Regarding type III collagen staining, a statisticallysigniﬁcant difference between the groups only occurred for
the biopsies performed at 150 days after induction, with
greater expression in GB controls (mean value, 5.50) than in
treated tendons (mean value, 3.14) of GB. No statistically
signiﬁcant differences (P < .05) occurred between the
analyses of the images of treated tendons (mean value,
4.98) of GA and controls (mean value, 5.10), (Fig. 3).
4. Discussion
The technique of tendon lesion induction using 2.5 mg
of type I collagenase diluted in sterile water, proved to be
a reliable technique for promoting experimental tendinitis
in horses, as previously reported [2,14,17].
The surgical collection of adipose tissue from the base of
the tail performed in this experiment also proved to be
viable [1,15,18]. The techniques used to obtain the stromal
vascular fraction from the adipose tissue and the posterior
culture for the expansion and isolation of the MSCs per-
formed in this study are similar to the techniques described
by Vidal et al. [18]. Results veriﬁed the adherence of MSCs
in culture in <48 hours, a fact in agreement with reports in
previously published data concerning the characteristics of
these cells to adhere to plastic when maintained in culture
conditions [19].
Minimum criteria for the characterization of human
MSCs were created: adherence to the plastic when main-
tained under culture conditions; express markers CD105,
CD73, and CD90; present no expression for markers CD45,
CD34, CD14 or CD11b, CD79a or CD19 and the human
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capacity to differentiate into osteoblasts, adipocytes, and
chondroblasts in vitro [20]. In this experiment, the immu-
nophenotypic characterization of the surface of the MSCs
used was conducted with the markers CD13, CD44, and
CD90. The results obtained suggest that the cells isolated
and expanded in culture should be MSCs [15]. Few markers
were used because of the low number of speciﬁc mono-
clonal antibodies available and evidence that certain
markers from other species do not cross-react with the
equine species [21].
The results of markers CD90 and CD44 in the ﬂow
cytometry analyses revealed compatibility with the results
obtained in experiments using MSCs derived from human
adipose tissue [22-25]. The nonexpression of MSCs derived
from equine adipose tissue by marker CD13 in this study
was also observed in a similar work that performed the
characterization of the surface of MSCs derived from equine
bone marrow [26]. However, this result differs from that
veriﬁed in MSCs derived from human adipose tissue, which
present expression of the marker CD13 [23-25].
No signiﬁcant increase in lesion cross-sectional area or
pain sensitivity occurred after the implantation of adipose-
derived MSCs, which is in agreement with the results
reported by Fortier and Smith [27], who indicated that the
implantation of bone marrow-derived MSCs did not
provoke worsening of the lesion or even tendon reaction,
with no increase in tendon area in ultrasonographic
imaging. The dose of progenitor cells used in this study
(10  106 cells) was within the range used by other authors
[27-29]. At present, there are no published studies evalu-
ating the optimal number of MSCs that should be used in
the treatment of tendinitis. It is possible that optimization
of theMSCs dose used in tendon therapy in the future could
improve the results of such studies [6]. One recent report
suggests that MSCs are potentially cytotoxic when injected
in high concentrations directly into tumor tissue (mela-
noma), liberating several angiogenesis inhibitor agents that
induce apoptosis and annul tumor growth, a process that
would be of enormous potential in cancer therapy [30].
Whether the administration of progenitor cells in high
concentrations in tendon injuries stimulates the release of
angiogenesis inhibitors remains unknown, though if this
does occur, it could result in the inhibition of tendon
healing, which is not desirable.
The use of adipose-derived MSCs proved to be safe with
the absence of neoplastic tissue formation at the lesion site
where the implantation was performed during the exper-
iment; however, Tasso et al. [31] reported that the possi-
bility of tumor (sarcoma) formation exists when using
implanted MSCs together with bioscaffold in mice.
Although no reports of teratoma formation after the
implantation of MSCs in horse tendon have been published,
this hypothesis must be considered when using this
process for tendon therapy [8].
Analysis of the results of the ultrasonographic evalua-
tion of the tendons is in agreement with previously pub-
lished reports, which afﬁrmed no signiﬁcant differences
occurred in the ultrasonographic parameters between
limbs that received cellular therapy and control limbs [1,6];
this is in contrast with a study by Barreira et al. [2], who
afﬁrmed that ultrasonographic differences in the meanvalues of the percentage of ruptured collagen ﬁbers in
a cross-sectional view occurred between the treatment and
control groups after the administration of bone marrow-
derived mononuclear cells. All ultrasonographic imaging
was obtained by the same operator using the same ultra-
sound equipment, to avoid variation due to different
operators and the use of different equipment. This
precaution is extremely important because it has previ-
ously been demonstrated that signiﬁcant interoperator
variability can occur when measuring the area of the same
tendon [32].
The results obtained in the present study concerning
histological analysis of the tendon are in agreement with
the ﬁndings of other studies [1,6], which afﬁrm that horses
that received MSCs therapy presented improved organi-
zation of tendon ﬁbers and diminished inﬂammatory
inﬁltrate.
According to Nixon et al. [1], no signiﬁcant differences
occurred in the statistical analysis of the immunohisto-
chemistry results regarding the proliferation and spatial
organization of type I collagen among the tendons that
received therapy with nucleated cells derived from adipose
tissue, but there was a reduction in the formation of type III
collagen in the tendons that received treatment. Schnabel
et al. [6] conducted a study using MSCs derived from bone
marrow as a form of therapy for experimental equine
tendinitis. They also reported no signiﬁcant differences
regarding the concentration of type I collagen between
treated and control tendons. The result described by Nixon
et al. [1] differs from that reported in this study for type I
collagen, but it is similar regarding the reduction of
collagen type III in the limbs that received cell implantation.
A possible explanation for the difference in collagen type I
expression is that, in the present study, cell implantation
was performed using MSCs derived from adipose tissue
that were isolated and cultured, whereas the other study
implanted nucleated cells derived from adipose tissue.
In this study, we opted for the use of adipose-derived
MSCs isolated and cultured in the laboratory rather than
mononucleated cells derived from adipose tissue contain-
ing MSCs in smaller quantities and other cells types.
Although this choice involves greater cost and is more
laborious, it has an advantage in that the procedure permits
isolation and expansion of the number of MSCs, thereby
avoiding the administration of a heterogenous cell pop-
ulation that can disturb the process of tendon repair. To our
knowledge, no harmful effects as a result of the presence of
certain cell types in adipose-derived mononucleated cells
have been reported [33]; however, according to McCarrel
and Fortier [34], a correlation exists between the concen-
tration of white blood cells contained in the material used
and increased genetic expression of catabolic agents in
tendons and ligaments.
Therefore, in agreement with Nixon et al. [1], the
injection of MSCs derived from adipose tissue into the
tendon lesion site promoted a reduction in inﬂammatory
cell inﬁltrate, suggesting that these cells possess an anti-
inﬂammatory effect on tendon regeneration or that they
possess some other anti-inﬂammatory effect such as the
stabilization or reduction of tendon ﬁber degeneration. The
precise mechanism of the anti-inﬂammatory effects of
these cells is largely unknown, though a combination of
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recruitment of local multipotent stem cells, and the liber-
ation of growth factors could all contribute to tendon repair
[35].
5. Conclusions
Histopathological analysis showed that the lesions that
received treatment with adipose-derived MSCs in both
groups (GA and GB) presentedmore organized and uniform
tissue repair as compared with the control limb, including
lower cellularity in the tendon, less inﬂammatory inﬁltrate,
lower ﬁbroblastic density, greater parallel arrangement of
the ﬁbers, larger extracellular matrix deposits, and greater
type I collagen expression. Although positive, future studies
are required involving a larger time interval for the evalu-
ation of tissue repair using adipose tissue as the stem cell
source, using different therapy protocols and different
analysis methods, including biomechanical and biochem-
ical analysis and genetic expression, to more fully elucidate
the efﬁcacy of cellular therapy in equine tendon repair.
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